Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
Opdualag chalks up another failure, this time in the extension of an approved use.
But investors remain unimpressed with the Nectin-4 ADC Corbus bought for just $7.5m.
Phase 1 data give investors a benchmark for mevrometostat's pivotal Mevpro-1 trial.
But the overall survival benefit in prostate cancer is still driven by HRR mutations.
AbbVie follows Gilead in throwing Xilio a lifeline.
The deal isn’t done, but would be Merck’s biggest oncology buy.
